Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03434379 · OUTCOME

Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab in the China Population

A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma · Source last updated 2023-10-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
Baseline and post-baseline on Day 1 (pre-dose) of Cycles 2, 3, 4, 8, 12, 16 (cycle length = 21 days) and treatment discontinuation visit (up to approximately 18 months)

Analysis population: The China ADA-evaluable population was defined as all participants in the China population who received any dose of atezolizumab and who had at least one post-baseline ADA assessment.

Groups in this outcome

Atezolizumab + Bevacizumab - China

Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Atezolizumab + Bevacizumab - China132

Reported measurements

Baseline

Analysis denominator · Participants

GroupSource count
Atezolizumab + Bevacizumab - China90
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Atezolizumab + Bevacizumab - China1.1Not reportedNot reportedNot reportedNot reported
Post-baseline

Analysis denominator · Participants

GroupSource count
Atezolizumab + Bevacizumab - China89
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Atezolizumab + Bevacizumab - China20.2Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1.1
    denoms
    1. counts
      1. group Id
        OG000
        value
        90
      units
      Participants
    title
    Baseline
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        20.2
    denoms
    1. counts
      1. group Id
        OG000
        value
        89
      units
      Participants
    title
    Post-baseline
denoms
  1. counts
    1. group Id
      OG000
      value
      132
    units
    Participants
groups
  1. description
    Participants in the China population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
    id
    OG000
    title
    Atezolizumab + Bevacizumab - China
param Type
NUMBER
population Description
The China ADA-evaluable population was defined as all participants in the China population who received any dose of atezolizumab and who had at least one post-baseline ADA assessment.
reporting Status
POSTED
time Frame
Baseline and post-baseline on Day 1 (pre-dose) of Cycles 2, 3, 4, 8, 12, 16 (cycle length = 21 days) and treatment discontinuation visit (up to approximately 18 months)
title
Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab in the China Population
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice